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Summary To evaluate the risk of endometrial cancer subsequent to breast cancer, a case-control study was
carried out in Denmark. Between 1943-1977, 115 cases of histologically confirmed endometrial carcinoma
developed more than 3 months after the diagnosis of a primary breast cancer in 51,638 women. A total of 235
breast cancer patients with no second primary cancer were matched to the cases on age, calendar year of
diagnosis, and survival with an intact uterus. Identification of cases and controls relied upon records available
in the Danish Cancer Registry. Information on risk factors and reproductive histories was abstracted from
hospital records. Increased relative risks (RR) for endometrial cancer were associated with menopausal
oestrogen use (RR=4.9), nulliparity (RR =2.1), late age at natural menopause (RR =2.9), and pelvic
irradiation (RR= 1.4). No association was apparent for drugs used to treat breast cancer. This study indicates
that breast and endometrial cancer share several common aetiologic factors and that studies of second
primary cancers have the potential to provide information on risk factors other than those associated with
therapy.
Several studies indicate that breast cancer patients
have an increased risk of developing subsequent
endometrial cancer (Schoenberg, 1977; Kelsey &
Hildreth, 1983). This may reflect a common
aetiology of the two cancers (Armstrong, 1979) as
well as the influence of various treatments for
breast cancer (Hoover et al., 1976). Such therapies
include irradiation to the pelvic area and sex
hormones, especially oestrogen.
The risk of endometrial cancer associated with
oestrogen therapy for breast cancer was previously
investigated in a cohort analysis by Hoover et al.
(1976). They reported a 3- and 2-fold increase in
risk, respectively, when oestrogens were given
during an initial or subsequent course of breast
cancer treatment. Their data on oestrogen use,
however, derived from information in cancer
registry records, and all treatments classified as
"hormones" were presumed to be oestrogens.
Moreover, no specification of type of oestrogen,
dose and duration of treatment was available.
A case-control study of endometrial cancer in
women previously diagnosed with breast cancer,
conducted simultaneously in Denmark and USA,
was initiated to evaluate further the risk associated
with oestrogen therapy and other factors suspected
to affect the risk of endometrial cancer. This paper
communicates the results of the Danish series.
Materials and methods
Both cases and controls were selected from the
Danish Cancer Registry, which has a virtually
complete registration of all cancers occurring in the
entire Danish population since 1943. The case
group was defined as women who developed a
primary endometrial cancer at least 3 months after
a diagnosis of breast cancer between 1943-1977.
Among 51,638 women diagnosed with breast
cancer, 138 cases of endometrial cancer were
identified. Twelve cases (8.7%) were excluded
because the source of exposure information
(hospital records - see below) had been destroyed
or could not be located. Six women with sarcomas,
4 with other mixed tumours, and one with no
histology report were excluded, leaving 115 cases
with histologically confirmed carcinomas of the
endometrium available for analysis.
Among breast cancer patients with no subsequent
malignancies, 235 were chosen as controls. These
were individually matched to the cases on the
following criteria: calendar year of breast cancer
diagnosis (within same 5-year calendar period, e.g.
1943-47, 1948-52 etc.), age at breast cancer
diagnosis (±3 years), and length of survival with
an intact uterus, A control must have survived for
at least as long as her corresponding case, and must
not have had a hysterectomy before the date the
case developed endometrial cancer.
Information on treatment for breast cancer
[surgery, radiation, chemotherapy, and hormones
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(oestrogens, androgens, other steroids)], and
potential risk factors for endometrial cancer
(marital status, height, weight, diabetes,
hypertension, parity, ages at menarche and
menopause, use of oestrogens and oral
contraceptives) was abstracted from the hospital
records of cases and controls by one of the authors
(ME). To verify the endometrial cancer diagnosis,
pathology reports were examined and information
on histology, grade and stage of disease obtained.
Comparisons between cases and matched controls
for all variables of interest were made by the
conditional logistic regression methods described in
Breslow & Day (1980). The computer program used
(Lubin, 1981) provides estimates of relative risks
(for both dichotomous and categorized variables)
and corresponding estimates of precision. If the
95% confidence interval does not contain 1.0, then
the relative risk is considered significant at the 5%
level. In the analysis of a particular variable, the
information for each set (a case and her
corresponding controls) is used unless the value is
missing for the case, or for all the controls in the
set.
Continuous variables were grouped into
"categories", i.e. non-overlapping intervals.
Calculations of relative risks between each category
and a chosen reference category were made using
dummy indicator variables for the categories. For
these categorized variables, trend tests were made
by taking the midpoint of each category as the
representative value or score. For open-ended
categories, for which there is some arbitrariness of
choice, the scores were chosen so that all scores
were equidistant from another.
For example, the variable menopausal age was
grouped into 4 categories: <45, 45-49, 50-54,
>54, and the scores were taken as: 42, 47, 52, and
57, respectively. One-sided statistical tests were
presented in most instances where the factor under
study, e.g. menopausal age, has been previously
found to be positively associated with the risk of
endometrial cancer.
Results
The mean age at breast cancer diagnosis was 59.8
years for cases and 59.5 years for controls, and the
mean survival from breast cancer diagnosis to
development of endometrial cancer and
corresponding year for controls was 10.8 and 12.1
years respectively.
Table I summarizes the risk of developing
endometrial carcinoma associated with selected
personal characteristics and medical conditions.
Women who had never given birth had twice the
risk of parous women. When the relative risk was
Table I Relative risk of endometrial cancer associated with various personal
characteristics and medical conditions among breast cancer patients
No. of No. of No. of Relative P-value
strata exposed exposed risk for
Factors Categories matcheda cases controls (95% Cl)b trendc
Marital status Never/ever 115 23 37 1.4 (0.8-2.6)
Age at menarche <13/13+ 44 11 12 1.5 (0.5-4.3)
Age at natural <45 79 7 26 1.0 (R)d 0.057
menopause 45- 26 52 1.4 (0.5-4.1)
50- 50 85 1.8 (0.7-4.9)
55+ 7 7 2.9 (0.7-12.5)
Nulliparity None/ 106 42 44 2.1 (1.2-3.7)
1 + children
Parity 0 106 42 44 1.0 (R) 0.018
1-2 45 108 0.5 (0.3-0.8)
3-4 18 49 0.5 (0.2-1.0)
5+ 5 13 0.4 (0.1-1.2)
Diabetes yes/no 115 11 22 1.1 (0.5-2.4)
Hypertension yes/no 104 24 50 1.0 (0.5-1.8)
aThe varying numbers are due to the exclusion of persons with missing information
on particular variables.
b95% confidence intervals of the relative risk.
cOne sided P-value for significance of trend in the relative risk.
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set to unity for nulliparous women, there was a
significant trend (P=0.02) of decreasing risk with
more childbirths. Among women who experienced a
natural menopause, the relative risk rose with
increasing age at menopause to 2.9 for menopause
after age 54, though the trend in the relative risk
was of borderline significance (P=0.06). A slight,
but not statistically significant, elevation of risk
appeared to be associated with early age at
menarche; however, the availability of information
on this variable in hospital records was especially
poor. No significant associations were found with
other factors such as marital status, diabetes or
hypertension.
The risk of endometrial carcinoma in relation to
body weight and height is presented in Table II. No
clear trend of increasing relative risk with
increasing height was found. The heaviest women
had significantly greater risk than the light ones,
although the trend for weight was of borderline
significance (P=0.06). To estimate relative weight,
Quetelet's index (weight/height2) was used. Women
who were especially overweight appeared to be at
highest risk (RR =2.3) for development of
endometrial cancer, but once again the numbers
were small and the trend of marginal significance
(P=0.06).
Table III shows that usage of oestrogens for
menopausal symptoms primarily prior to the
diagnosis of breast cancer was associated with a
relative risk of 4.9 (95% confidence intervals (CI):
2.0-12) for development of endometrial cancer,
whereas oestrogens used in breast cancer treatment
yielded a relative risk of 0.6 (95% CI: 0.2-1.8).
Although the number of women exposed to
oestrogens was small, an attempt to evaluate
duration of use was made by grouping women by
whether they were treated for less than one year, or
for one year or more. Among those treated the
longest, the risk associated with oestrogens for
menopausal symptoms rose to 8.0 (95% CI: 1.7-38)
and for breast cancer treatment to 1.7 (95% CI:
0.4-6.9). Androgens and steroids were not related
to the risk of endometrial cancer. For
chemotherapy, which in all instances included
cyclophosphamide, the risk was found elevated,
though not significantly.
It was not possible to evaluate oral
contraceptives, since approximately 75% of the
women experienced their menopause before 1960
and therefore never had the opportunity to use this
form of birth control. Similarly, the antioestrogen
tamoxifen, which was introduced in breast cancer
treatment in the mid 1970s, could not be
meaningfully evaluated. No case and only one
control was treated with tamoxifen.
Radiation of the ovaries or the pelvis appeared
to increase the risk of endometrial cancer. Since
there were very few exposed in each of these
categories, those who received any pelvic irradiation
Table II Relative risk of endometrial cancer in relation to height and weight among
breast cancer patients
No. of No. of No. of Relative P-value
strata exposed exposed risk for
Factor Categories matcheda cases controls (95% Cl)b trend'
Height <61 100 26 37 1.0 (R)d 0.19
(inches) 61- 27 60 0.7 (0.4-1.5)
63- 31 57 1.0 (0.5-2.2)
65- 18 27 1.2 (0.5-2.8)
67+ 4 5 1.4 (0.3-6.6)
Weight < 125 104 18 52 1.0 (R) 0.055
(lbs) 125- 46 73 1.9 (0.9-4.2)
150- 29 56 1.7 (0.8-3.9)
175+ 16 22 2.7 (1.0-7.2)
Quetelet's
index <22 100 25 50 1.0 (R) 0.055
(kgm 2) 22- 25 49 0.9 (0.5-1.9)
25- 23 39 1.1 (0.5-2.5)
28- 16 30 1.2 (0.5-3.0)
31 + 17 18 2.3 (0.9-6.2)
aThe varying numbers are due to the exclusion of persons with missing information
on particular variables.
b95% confidence intervals of the relative risk.
cOne sided P-value for significance of trend in the relative risk.
dR denotes reference category.690 M. EWERTZ et al.
Table III Risk of endometrial carcinoma following breast cancer in
relation to drug exposure
No. of No. of No. of Relative
Categories strata exposed exposed risk
Drug ofuse matcheda cases controls (95% CJ)b
Oestrogens Any/none 115 21 15 4.9 (2.0-12)
for menopause 1 +yrs/none 105 11 7 8.0 (1.7-38)
Breast cancer treatment:
Oestrogens Any/none 113 5 15 0.6 (0.2-1.8)
1 +yrs/none 109 4 4 1.7 (0.4-6.9)
Androgens Any/none 112 2 9 0.5 (0.1-2.3)
Other steroids Any/none 113 5 17 0.6 (0.2-1.8)
Chemotherapy Yes/no 112 4 4 2.2 (0.5-10)
aThe varying numbers are due to the exclusion of persons with missing
information on particular variables.
b95% confidence intervals of the relative risk.
were combined. However, none of the relative risks
were significantly different from unity (Table IV).
Radiation to the breast and axilla did not affect the
risk of developing endometrial cancer.
The risk associated with personal characteristics
and exposure to drugs was examined in relation to
age at which the cases developed endometrial
cancer. No appreciable differences between women
aged 65 years or more and younger women were
observed for most factors, although there was a
Table IV Risk of endometrial carcinoma following
breast cancer in relation to radiation exposure
No. of No. of No. of Relative
strata exposed exposed risk
Factorsa matchedb cases controls (95% Cl)C





breast 115 95 219 1.0 (0.5-1.8)
ovaries 113 6 13 1.3 (0.4-3.6)
pelvic area 113 3 2 2.6 (0.4-16.0)
Any pelvic 104 14 20 1.4 (0.6-3.0)
irradiationd
'All relative to those not irradiated.
bThe varying numbers are due to the exclusion of
persons with missing information on particular variables.
o95i confidence intervals of the relative risk.
dIncludes: Radiation-induced menopause, radiation to
ovaries and/or radiation to pelvic area.
suggestion that the relative risk was higher for
menopausal oestrogen use among older (RR=7.8;
95% CI: 2.4-25) than younger women (RR=2.6,
95% CI: 1.1-6.6).
Discussion
In the absence of a previous diagnosis of breast
cancer the most consistently reported risk factors
for endometrial cancer are nulliparity, late age at
menopause, obesity, and oestrogens for menopausal
symptoms (Elwood et al., 1977; Ewertz, 1981;
Kelsey et al., 1982; La Vecchia et al., 1982;
MacMahon, 1974; Salmi, 1979; Wynder et al.,
1966). Our results closely agree with those studies.
This consistency suggests that studies of second
primary cancers have the potential to provide
information on risk factors other than those
associated with therapy.
The epidemiology of breast and endometrial
cancer appear similar in many respects, and both
the geographical correlation of these two
malignancies and the frequency of occurrence
within the same individual suggest that they may
have aetiologic factors in common (Kelsey &
Hildreth, 1983). Such factors include nulliparity,
obesity, and late menopause, possibly mediated by
a hormonal mechanism (Henderson et al., 1982).
These are associated with an increased breast
cancer risk and were, in the present study,
associated with increased risk of endometrial
cancer. Interestingly, since both cases and controls
had breast cancer, an inadvertant "overmatching"
on these common factors was possible. However,
any overmatching would tend to reduce theENDOMETRIAL CANCER AFTER BREAST CANCER IN DENMARK 691
estimates of the relative risk, and the "true"
associations would be even stronger than observed.
One of the main purposes of the study was to
examine the risk of endometrial cancer in relation
to exogenous oestrogens. Our results on usage for
menopausal symptoms with five- to eight-fold
increases in relative risk, depending on duration of
use, agree well with what is reported in the
literature (Kelsey & Hildreth, 1983). Duration of
use probably also explains that the oestrogen
associated risk was higher among older women,
since these women used oestrogens for longer
periods than the younger ones. The age effect is
unlikely to be due to confounding by menopausal
age, because adjustment for this factor did not alter
the risks significantly.
We find it puzzling that no elevated risk was
clearly associated with oestrogen treatment for
breast cancer, but this may be due to the low doses
and short durations of treatment involved. When
short term users are excluded, i.e. those with a
duration of use less than one year, the relative risk
increased to 1.7, but the calculation was based on
small numbers. This relative risk is also compatible
with that obtained for the former study of
oestrogen therapy for breast cancer (Hoover et al.,
1976). Others (Hulka et al., 1980; Kelsey et al.,
1982; Shapiro et al., 1980) have shown that
oestrogens must be used for a period of 2-3 years
before a significant increase in risk can be detected.
Information on doses of oestrogen was well
documented for breast cancer therapy, but
unfortunately not so for treatment of menopausal
symptoms, and a comparison of dosage could not
be done.
Several sources of bias might affect the
association between oestrogen and endometrial
cancer (Cramer & Knapp, 1979). In the present
study, information on menopausal oestrogen use
was obtained almost exclusively at the time of the
breast cancer diagnosis. The possibility of recall
bias was thus minimal. Since the ascertainment of
oestrogen use occurred at least three months prior
to the diagnosis of endometrial cancer, detection
bias was also unlikely.
Ionizing radiation is a well known carcinogen,
and the incidence rate of almost all cancers appears
to increase after irradiation (Boice, 1981). Studies
of women treated with radiation for benign
gynaecological disorders (Dickson, 1969; Smith &
Doll, 1976; Wagoner, 1984) and for cervical cancer
(Boice et al., 1984; Dickson, 1972) have found
uterine cancer to be associated with radiotherapy of
the pelvis. Our results also suggest an increased risk
of endometrial carcinoma following pelvic
irradiation, although due to the small number of
exposed women, chance could not be excluded as
an alternative explanation. No effect, however, was
observed for radiation to the breast and axilla.
In conclusion, this study provides some evidence
that endometrial cancer following breast cancer
seems to be the same disease as that developing in
previously healthy women, especially with respect
to the high risk associated with menopausal
oestrogen use. It also gives support to the
hypothesis that some common factors are likely to
be involved in the aetiology of breast and
endometrial cancers, in particular late age at
menopause, nulliparity and obesity. Because of the
small study size, it was not possible to produce a
conclusive evaluation of risk associated with
hormones or pelvic radiation used in breast cancer
treatment. However, this may be clarified when the
present data are combined with a similar study
conducted in the United States.
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